Proceedings of the British Pharmacological Society at http://www.pA2online.org/abstracts/Vol16lssue1abst025P.pdf.

## Is drug lipophilicity a robust predictor for potency of beta-cell K<sub>ATP</sub> channel block

P. Smith. Life Sciences, University of Nottingham, Nottingham, UNITED KINGDOM

**Introduction** The ability of sulphonylurea drugs to potently inhibit ATP-sensitive-potassium channels ( $K_{ATP}$ ) have revolutionised our understanding and treatment of hypoinsulinaemic disorders such as type II diabetes. However adverse hyperinsulinaemia with a variety of structurally diverse drugs unrelated to of sulphonylureas is demonstrated to arise from off target inhibition of  $K_{ATP}$  (1). By a retrospective analysis of published data, I demonstrate that the potency for non-sulphonylurea compounds that inhibit  $K_{ATP}$ , is dependent on their lipophilicity.

**Methods** Publications that measured  $K_{ATP}$  currents with either whole-cell or inside-out patch clamp in pancreatic beta-cells, beta-cell cell-lines or from cells expressing recombinant Kir6.2<sub>4</sub>/SUR1<sub>4</sub> constructs were examined (1). Log IC<sub>50</sub> values recorded in the presence of intracellular Mg<sup>2+</sup>, except where Mg<sup>2+</sup> did not affect drug action, were extracted. Log P values, pH range 7-9, were from DrugBank (2) else they were calculated from quantitative structural activity relationships with Chemicalize (3).

**Results** With the exception of sulphonylureas, the plC<sub>50</sub> of 23 drugs to block  $K_{ATP}$  were linearly correlated to their Log P (r = 0.91, p < 0.001). Linear regression revealed a slope coefficient insignificantly different to 1 (0.83 to 1.3, 95% C.l.) and a y intercept of 1.9 (1.3 to 2.6, 95% C.l.); a value indicative of a membrane concentration of 10 mM at the IC<sub>50</sub> for any drug. Expression studies with  $K_{IR}6.2\Delta C26$ , which forms K<sup>+</sup> channels in the absence of SUR1, show, where tested, that the channel pore is the predominant binding site for non-sulphonylureas (1). This finding is supported by drugs which block  $K_{ATP}$  with a potency unaffected by Mg<sup>2+</sup> a condition which uncouples the interaction between SUR1 and Kir6.2 (1). Further support for these ideas comes from diazoxide which opens  $K_{ATP}$  in the presence of intracellular Mg<sup>2+</sup> but blocks in its absence (4) with a plC<sub>50</sub> related to its Log P.

**Conclusion** For non-sulphonylurea drugs that inhibit  $K_{ATP}$  their pIC<sub>50</sub> is linearly related to Log P and is devoid of obvious structural or chemical motifs. Moreover, these data suggest that the action of these drugs occurs by a simple physiochemical disruption of the membrane bilayer environment and suggest that a prospective analysis of Log P for new drugs will help predict adverse hypoglycaemic action.

**References** (1) Gribble FM et al (2000) Br. J Pharmacol. 13 (2000) 756-760. (2) Drugbank http://www.drugbank.ca/ (3) Chemicalize www.chemicalize.org/ (4) Kozlowski RZ and Ashford ML (1992) Br. J Pharmacol. 107: 34-43.